Key points from article :
Many new drugs entering the German healthcare system have not been shown to add benefit.
Assessed 216 drugs entering the German market following regulatory approval from 2011 to 2017.
125 drugs (58%) did not have a proven added benefit over standard care.
Only 54 drugs (25%) showed a considerable or major added benefit.
Regulatory authorities should demand robust evidence to prove efficacy and safety of drugs.
Must revise the legal and regulatory framework and introduce new drug development models.
Study by Institute for Quality and Efficiency in Health Care, Cologne, Germany published in British Medical Journal.
